Halozyme Therapeutics Stock (NASDAQ: HALO) stock price, news, charts, stock research, profile.
Open | $44.080 |
Close | $43.150 |
Volume / Avg. | 1.032M / 1.024M |
Day Range | 43.120 - 44.210 |
52 Wk Range | 29.850 - 45.000 |
Market Cap | $5.417B |
P/E Ratio | 18.199 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 64 |
Short Interest | 8.75% |
Days to Cover | 8.41 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.
Other companies in Halozyme Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Ionis Pharmaceuticals (NASDAQ:IONS) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by JMP Securities on Wednesday, May 8, 2024. The analyst firm set a price target for 71.00 expecting HALO to rise to within 12 months (a possible 66.82% upside). 24 analyst firms have reported ratings in the last year.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $42.56 last updated May 10, 2024 at 6:20 PM EDT.
There are no upcoming dividends for Halozyme Therapeutics.
Halozyme Therapeutics’s Q2 earnings are confirmed for Tuesday, August 6, 2024.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.